Pradaxa: safety update owing to risk of serious haemorrhage

The MHRA has issued updated safety advice for the anticoagulant dabigatran (Pradaxa).

by
Concomitant use of antiplatelet agents with dabigatran increases the risk of major bleeding approximately three-fold | SCIENCE PHOTO LIBRARY
Concomitant use of antiplatelet agents with dabigatran increases the risk of major bleeding approximately three-fold | SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package